Speaker Profile
Ph.D., Associate Professor, UCSF
Biography
Justin Eyquem develops next-generation immune cell therapies for cancer and other diseases. He pioneered genome-engineering strategies to precisely reprogram T cells, including approaches that improve CAR-T cell function and enable therapeutic T cells to be engineered directly inside the body. His research spans fundamental discoveries in T-cell biology through preclinical development and clinical translation, with the goal of making engineered cell therapies more potent, precise, and accessible. At UCSF, he leads efforts to design and advance new gene-edited cell therapies into clinical trials and has contributed to innovations that facilitate their manufacturing. His work has been recognized with the Parker Fellow Award, the ASGCT Outstanding New Investigator Award, the Pew-Stewart Award for Cancer Research, and the Cancer Research Institute Lloyd J. Old STAR Award.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Razelle Kurzrock, Emory
PMWC Award Ceremony
• Antoni Ribas, UCLA Health (Luminary)
Featured Speakers
• Antoni Ribas, UCLA Health
• Gerold Meinhardt, Daiichi Sankyo
• Katy Rezvani, MD Anderson
• Javad Shahidi, BeOne
• Alicia Zhou, Cancer Research Institute
• Oren Gilad, Aprea Therapeutics
• Adam Palmer, UNC
• Trever Bivona, UCSF
• Laura Volta, Penn Medicine
• Vivek Subbiah, Stanford
• Mark Stewart, Friends of Cancer Research
Precision Immunotherapy After PD-1
Cells, bispecifics, ADCs, and new combination logic after checkpoint failure.
Biomarkers That Matter
Selecting patients for immunotherapy and targeted therapy with decision-grade biomarkers.
Resistance Biology & Adaptive Combination Strategies
How tumors adapt, and how to sequence therapy around that biology.
Which Immune Cells Can Be Programmed In Vivo?
The next wave of immune-cell engineering and where it may matter first.
Rare Cancers, Basket Trials & N-of-1 Playbooks
Moving from histology-agnostic evidence to individualized precision oncology.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
